Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations.

ABSTRACT:

Background

Cancers that do not respond to immunotherapy typically harbor a non-T cell-inflamed tumor microenvironment (TME), characterized by the absence of type I/II interferon (IFN) signaling and CD8⁺ T cell infiltration. We previously reported IDH1 somatic mutations were enriched in non-T cell-inflamed tumors across tumor types. Consistent with this, mutant IDH1 (mIDH1) has been demonstrated to drive immune exclusion through metabolic reprogramming of the TME, and IDH inhibition enhanced anti-tumor immunity in preclinical models. Based on these pan-cancer observations, we conducted a Phase II study assessing the preliminary activity of ivosidenib, an IDH1 inhibitor, in combination with nivolumab, an anti-PD1 antibody, in patients with mIDH1 advanced solid tumor

SUBMITTER: Nguyen MK 

PROVIDER: S-EPMC12330440 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature